Is the U.S. Ready for Value-based Pricing of Drugs?

The federal government’s move to switch to value-based pricing of drugs for one category of public health plans could potentially have far-reaching effects, say experts.

The Joseph H. Lauder Institute
256 South 37th street
2nd Floor
Philadelphia, PA 19104-6330